Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes.

PURPOSE We present long-term observations on photoselective vaporization of the prostate in a prospectively studied cohort of men with obstructive benign prostatic hyperplasia. MATERIALS AND METHODS Obstructive benign prostatic hyperplasia in 94 men was treated with transurethral near contact vaporization with potassium-titanyl-phosphate laser with the patient under general or spinal anesthesia. Baseline characteristics, perioperative data, postoperative outcomes and adverse events were recorded. RESULTS Mean prostate volume was 45 ml (range 13 to 136). Mean lasing time was 47 minutes (range 10 to 99), and there was minimal blood loss and no evidence of fluid absorption. All 94 men were outpatients and all but 1 became catheter-free in less than 24 hours. Baseline mean American Urological Association symptom index score was 22, quality of life score 4.5, peak urinary flow rate 7.8 ml per second and post-void residual urine volume 197 ml. After surgery percentage changes from baseline in mean values of these parameters, reflecting significant (p <0.0001) improvement at 1, 2, 3 and 5 years, ranged from 83% to 88%, 86% to 90%, 170% to 252% and 76% to 89%, respectively. Complications were mild, and included transient dysuria (6%), delayed hematuria (3%), bladder neck contracture (2%) and 2-day retention (1%). No patient had incontinence or newly developed impotence, but up to 26% of the sexually active men experienced retrograde ejaculation. Postoperatively, low stage prostate cancer was detected in 5% of the patients. CONCLUSIONS : Despite limitations our long-term experience and the literature suggest that significant improvements in symptomatic and urodynamic outcomes of photo-selective vaporization of the prostate are achievable and sustainable.

[1]  Tullio Sulser,et al.  High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. , 2005, The Journal of urology.

[2]  T. Wilt,et al.  Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review. , 2003, The Journal of urology.

[3]  D. Bostwick,et al.  Potassium-titanyl-phosphate laser vaporization of the prostate: a comparative functional and pathologic study in canines. , 1996, Urology.

[4]  D. M. Barrett,et al.  Laser prostatectomy: two and a half years' experience with aggressive multifocal therapy. , 1996, Urology.

[5]  D. M. Barrett,et al.  High-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. , 1998, Urology.

[6]  S. Kaplan,et al.  High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. , 2004, Urology.

[7]  P. Gilling,et al.  Long‐term results of high‐power holmium laser vaporization (ablation) of the prostate , 2003, BJU international.

[8]  D. Bostwick,et al.  High-power (60-watt) potassium-titanyl-phosphate laser vaporization prostatectomy in living canines and in human and canine cadavers. , 1997, Urology.

[9]  U. Nseyo,et al.  Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. , 2004, The Journal of urology.

[10]  L. Kiemeney,et al.  Long-term followup of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. , 2001, The Journal of urology.

[11]  D. M. Barrett,et al.  High power potassium-titanyl-phosphate laser vaporization prostatectomy. , 2000, The Journal of urology.